Biotech Investor Adds $3 Million to Krystal Biotech
A biotech investor has increased their stake in Krystal Biotech by $3 million, as the company reported revenues reaching $389 million in 2025.
Results for “Krystal Biotech”
6 stories found
Krystal Biotech, Inc. Q4 2025 Earnings Call Summary
A summary of Krystal Biotech, Inc.'s Q4 2025 earnings call outlines the company's financial performance and strategic updates.
Jefferies Raises Price Target on Krystal Biotech to $371
Jefferies has increased its price target for Krystal Biotech, Inc. (KRYS) to $371, while maintaining a Buy rating on the stock.
Krystal Biotech Q4 Earnings Call Highlights
Krystal Biotech's Q4 earnings call highlights are now available, detailing the company's financial performance and outlook.
Krystal Biotech Targets Global VYJUVEK Expansion with Italy Launch
Krystal Biotech plans to expand VYJUVEK globally, with a launch in Italy scheduled for the second half of 2026, while maintaining a strong gross margin outlook.
Krystal Biotech Beats Q4 Top-Line and Bottom-Line Estimates, Initiates FY26 Outlook
Krystal Biotech exceeded both revenue and earnings estimates for the fourth quarter and has initiated its financial outlook for fiscal year 2026.